BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/16/2025 5:36:38 AM | Browse: 10 | Download: 23
 |
Received |
|
2024-08-26 03:10 |
|
Peer-Review Started |
|
2024-09-05 01:12 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2025-01-08 12:26 |
|
Revised |
|
2025-01-18 04:03 |
|
Second Decision |
|
2025-02-05 02:45 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2025-02-06 08:54 |
|
Articles in Press |
|
2025-02-06 08:54 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2025-02-08 03:21 |
|
Typeset the Manuscript |
|
2025-02-12 09:58 |
|
Publish the Manuscript Online |
|
2025-04-16 05:36 |
| ISSN |
2220-315x (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Letter to the Editor |
| Article Title |
MicroRNA-155 modulation by renin-angiotensin system inhibitors may underlie their enigmatic role in COVID-19
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Konstantinos I Papadopoulos, Alexandra Papadopoulou and Tar Choon Aw |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Konstantinos I Papadopoulos, Chief Physician, MD, PhD, Department of R and D, THAI StemLife, 566/3 THAI StemLife Bldg., Soi Ramkhamhaeng 39 (Thepleela 1), Prachaouthit Road, Wangthonglang, Bangkok 10310, Thailand. kostas@thaistemlife.co.th |
| Key Words |
Angiotensin converting enzyme inhibitors; Angiotensin II type 1 receptor blocker; COVID-19; MicroRNA; Mineralocorticosteroid receptor antagonists; MicroRNA-155; Renin-angiotensin system inhibitors; SARS-CoV-2; Sodium-glucose transporter 2 |
| Core Tip |
The role of renin-angiotensin system (RAS) inhibition in coronavirus disease 2019 (COVID-19) remains enigmatic. Novel insights involving interference of microRNA-155 (miR-155) and erythropoietin (EPO) levels support a detrimental role by RAS inhibitors in the elderly and in co-morbidities. Current pharmacological interventions in COVID-19 employing RAS inhibition should consider these complex but potentially detrimental miR-155 effects. Future research should address the knowledge gap on how RAS inhibition affects miR-155 while therapeutic strategies should focus on pharmacological interventions that restore EPO and miR-155 levels and functionality. The use of tissue specific miRNA-analogs could become a reality by then. |
| Publish Date |
2025-04-16 05:36 |
| Citation |
<p>Papadopoulos KI, Papadopoulou A, Aw TC. MicroRNA-155 modulation by renin-angiotensin system inhibitors may underlie their enigmatic role in COVID-19. <i>World J Exp Med</i> 2025; 15(2): 100748</p> |
| URL |
https://www.wjgnet.com/2220-315x/full/v15/i2/100748.htm |
| DOI |
https://dx.doi.org/10.5493/wjem.v15.i2.100748 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
